Michelle Mitchell – CEO, Multiple Sclerosis Society, UK
Michelle Mitchell, CEO of the Multiple Sclerosis Society in the UK since 2013, discusses her charity’s aims; their focus on research and development; funding in the face of Brexit; and…
Address: Bristol-Myers Squibb Pharmaceuticals Limited (Uxbridge), MS House, Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex, UB8 1DH, United Kingdom
Tel: +44 (0)1895 523000
Since 1858, medicines made by Bristol-Myers Squibb have helped millions of patients around the world fight serious diseases such as cancer, heart disease, diabetes, HIV/AIDS, chronic hepatitis B, rheumatoid arthritis and various psychiatric disorders.
From those early days, the company has been developing our offering to better meet the needs of patients. By combining the best elements of a leading-edge biotech company with the resources of a major pharmaceutical company, BMS is transforming into a new kind of enterprise: a next-generation BioPharma leader.
At the heart of this BioPharma strategy are the medicines that give meaningful hope to patients and physicians and bring value to its shareholders and customers. Since 2002, BMS introduced eight new products for the treatment of numerous serious diseases.
As well as all these products now on the market, scores of additional investigational medicines are advancing through the company’s pharmaceutical development pipeline. In fact, Bristol-Myers Squibb is recognised as having one of the most productive pipelines in the industry.
Over the years, Bristol-Myers Squibb and its employees have received awards and recognition. We have been listed as one of the best companies to work for by The Sunday Times. We have also been acknowledged as an industry leader in environment, health and safety management.
Finally, our philanthropic programmes have given new hope to some of the world’s most vulnerable citizens.
Michelle Mitchell, CEO of the Multiple Sclerosis Society in the UK since 2013, discusses her charity’s aims; their focus on research and development; funding in the face of Brexit; and…
Recipient of the 2018 Brain Prize for research for groundbreaking research on the generic and molecular basis of Alzheimer’s Disease, the UCL’s Professor John Hardy discusses recent progress in dementia…
Tim de Gavre, country head of Sandoz UK, discusses the role of biosimilars in driving innovation, the threats and opportunities of Brexit to the biosimilars industry, and how Sandoz partners…
Mike Belton of the British Swiss Chamber of Commerce discusses the capabilities of the organization, its role within the British and Swiss investment ecosystem, and how Switzerland can act as…
John Smith, chief executive of the PAGB, the UK’s consumer healthcare industry association, discusses the potential impacts of Brexit on the PAGB’s members, the importance of consumer healthcare to the…
Sarah Haywood, CEO of MedCity, the life science cluster for London, Oxford and Cambridge in the southeast of England, discusses the organization’s strategy, key achievements, Brexit, and supporting SMEs. Why…
In an exclusive interview at the BioPharma Ambition Conference 2016 in Dublin, Sir Andrew Dillon, founding CEO of the UK National Institute for Health and Care Excellence (NICE), shares his…
Lord Philip Hunt, a former UK health minister during the Blair and Brown governments, shares his thoughts on procurement in healthcare, structural change and its impact, and how funds may…
British consultant, speaker and author, Richard Barker – a key opinion leader on UK healthcare – gives his take on the recently launched ‘Life Sciences Industrial Strategy’, the importance of…
Warwick Smith, director general of the British Generic Manufacturers Association (BGMA), discusses the potential impact of Brexit and recent policy changes on the British generics industry and extols the benefits…
Simon Gillespie of the British Heart Foundation (BHF), the UK’s leading national heart charity, outlines the organization’s mission, the issues surrounding translational research, and the potential impact of Brexit on…
Hilary Evans of Alzheimer’s Research UK (ARUK), the UK’s leading national research charity in the field of dementia, discusses her organization’s mission; the growing awareness of, and investment in, dementia…
See our Cookie Privacy Policy Here
